Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA <20 ng/ml

被引:14
作者
Chang, Tsung-Hsin [1 ]
Lin, Wun-Rong [1 ,2 ]
Tsai, Wei-Kung [1 ,2 ]
Chiang, Pai-Kai [1 ,2 ]
Chen, Marcelo [1 ,2 ,3 ]
Tseng, Jen-Shu [1 ]
Chiu, Allen W. [1 ,4 ]
机构
[1] MacKay Mem Hosp, Dept Urol, 92,Sect 2,Zhongshan N Rd, Taipei 10449, Taiwan
[2] Mackay Med Coll, 46,Sect 3,Zhongzheng Rd, Taipei, Taiwan
[3] Mackay Jr Coll Med Nursing & Management, 92,Shengjing Rd, Taipei 11272, Taiwan
[4] Natl Yang Ming Univ, Sch Med, 145,Zhengzhou Rd, Taipei 10341, Taiwan
关键词
Prostate cancer; PSA; Transition PSA; TRANSITION ZONE; ANTIGEN DENSITY; ADENOCARCINOMA; VOLUME; EPIDEMIOLOGY; DIAGNOSIS; BIOPSY;
D O I
10.1186/s12894-020-00717-z
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe current study aimed to compare the efficacy of transition zone PSA density (TZPSAD) with traditional PSA and PSA density (PSAD), for the diagnosis of prostate cancer (PCa) in Taiwanese males.MethodsMen with PSA between 4.0 and 20.0 ng/ml who underwent a transrectal ultrasound (TRUS) guided prostate biopsy between the studied period were retrospectively identified. The demographic data, PSAD and TZPSAD were calculated in all patients. Receiver operating characteristic (ROC) curves were used to analyze the accuracy of a positive PCa diagnosis.ResultsThe area under the ROC (AUC) was 0.615, 0.748 and 0.746 for PSA, PSAD and TZPSAD, respectively. The best cut-off of value for TZPSAD in predicting PCa in men with a PSA of 4.0-10.0 ng/ml was 0.367 ng/ml/ml with a sensitivity of 50% and a specificity of 77.5%. In men with a PSA of 10.1-20.0 ng/ml, the best cut-off value was 0.454 ng/ml, with a sensitivity of 74.8% and specificity of 70.9%.ConclusionThe use of TZPSAD can improve the efficiency and specificity of PSA for the diagnosis of PCa in Taiwanese men with PSA 4.0-20.0 ng/ml. TZPSAD efficiency was similar to PSAD but TZPSAD had better cancer specificity.
引用
收藏
页数:6
相关论文
共 23 条
  • [1] Aksoy Y, 2003, ANN CLIN LAB SCI, V33, P320
  • [2] Transition Zone Prostate-specific Antigen Density Could Better Guide the Rebiopsy Strategy in Men With Prostate Inflammation at Initial Biopsy
    Amini, Erfan
    Pishgar, Farhad
    Ayati, Mohsen
    Jamshidian, Hassan
    Arbab, Amir
    Gooshe, Maziar
    Nowroozi, Mohammad Reza
    [J]. UROLOGY, 2015, 86 (05) : 985 - 990
  • [3] THE USE OF PROSTATE SPECIFIC ANTIGEN DENSITY TO ENHANCE THE PREDICTIVE VALUE OF INTERMEDIATE LEVELS OF SERUM PROSTATE SPECIFIC ANTIGEN
    BENSON, MC
    WHANG, IS
    OLSSON, CA
    MCMAHON, DJ
    COONER, WH
    [J]. JOURNAL OF UROLOGY, 1992, 147 (03) : 817 - 821
  • [4] Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates
    Culp, MaryBeth B.
    Soerjomataram, Isabelle
    Efstathiou, Jason A.
    Bray, Freddie
    Jemal, Ahmedin
    [J]. EUROPEAN UROLOGY, 2020, 77 (01) : 38 - 52
  • [5] Prostate specific antigen density of the transition zone for early detection of prostate cancer
    Djavan, B
    Zlotta, AR
    Byttebier, G
    Shariat, S
    Omar, M
    Schulman, CC
    Marberger, M
    [J]. JOURNAL OF UROLOGY, 1998, 160 (02) : 411 - 418
  • [6] Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context
    Draisma, Gerrit
    Etzioni, Ruth
    Tsodikov, Alex
    Mariotto, Angela
    Wever, Elisabeth
    Gulati, Roman
    Feuer, Eric
    de Koning, Harry
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (06): : 374 - 383
  • [7] The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes
    Elliott, Christopher S.
    Shinghal, Rajesh
    Presti, Joseph C., Jr.
    [J]. JOURNAL OF UROLOGY, 2008, 179 (05) : 1756 - 1761
  • [8] Prostate-Specific Antigen-Based Screening for Prostate Cancer Evidence Report and Systematic Review for the US Preventive Services Task Force
    Fenton, Joshua J.
    Weyrich, Meghan S.
    Durbin, Shauna
    Liu, Yu
    Bang, Heejung
    Melnikow, Joy
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (18): : 1914 - 1931
  • [9] Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
    Ferlay, J.
    Colombet, M.
    Soerjomataram, I.
    Mathers, C.
    Parkin, D. M.
    Pineros, M.
    Znaor, A.
    Bray, F.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (08) : 1941 - 1953
  • [10] Fujinami Kiyoshi, 2005, Nihon Hinyokika Gakkai Zasshi, V96, P475